Press Release

GC Therapeutics Appoints Stem Cell Therapy Leader Stefan Irion, MD, as Chief Scientific Officer

Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases

SonoThera Presents New Preclinical Data at MDA 2026 Highlighting RIPPLE™ as an Efficient, Scalable, Nonviral Platform for Full-Length Dystrophin Delivery in DMD

GC Therapeutics Appoints Kate Haviland as Board Chair and Provides Corporate Update

SonoThera Launches $125M Series B at 44th J.P. Morgan Healthcare Conference to Advance Multiple Genetic Medicine Programs Toward First-in-Human Studies

Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients

Truvian Appoints Renowned Physician-Scientist and Diagnostic Innovator Dr. Michael Mina as Chief Medical and Strategy Officer

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

ThirdLaw Molecular Rebrands as Ladder Bio; Announces $5.5M Seed Financing Led by Medical Excellence Capital and Appoints Eric Heil as Chief Executive Officer

Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson’s Disease